On June 1, 3SBio rose 8% in regular trading, trading at HK$19.79/share, with trading volume of HK$137 million. The stock continues to be propelled by clinical data unveiled at the ASCO Annual Meeting.

On the news front, 3SBio's core pipeline asset, PD-1/VEGF bispecific antibody SSGJ-707, had two clinical studies selected for presentation at the ASCO Annual Meeting, with one earning a Rapid Oral Communication slot. According to published abstracts, the Phase II study of SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with a median PFS of 12.4 months. In first-line treatment of endometrial cancer combined with chemotherapy, confirmed ORR reached 85.7% and 80.0%, respectively—data widely regarded as impressive in the field.

Within the Biotechnology sector, several peers also posted gains, with AKESO up 6.94%, SKB BIO up 5.06%, and REMEGEN up 2.54%, reflecting broad sector strength that further bolstered market sentiment around 3SBio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)